Clinical Trial Results:
            Extension protocol for patients with Chronic Myelogenous Leukemia (CML), Malignant Melanoma (MM) or Renal Cell Carcinoma (RCC) that have responded to treatment with Pegylated-interferon α-2a (PEG-IFN) or Roferon-A in prior clinical studies.
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2004-002093-30 | 
    Trial protocol  | 
        ES | 
    Global completion date  | 
        
                                    01 Jan 2008
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    08 Jul 2016
                             
         | 
    
    First version publication date  | 
        
                                    26 Jun 2015
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                NO17754_Synopsis | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.